Medicare Advantage programs receive boost while physicians wait
The AMA pointed out that while Congress allowed yet another round of physician Medicare payment cuts, MA plans received a healthy boost.
Related Articles
Kidney Compass: Introducing the PARASOL Initiative, with Laura Mariani, MD, MS, and Daniel Gale, PhD, MB BChir
In part 1 of 4 from this episode, the discussion focuses on the backgrounds of guests Laura Mariani, MD, MS, and Daniel Gale, PhD, MB…
Tariffs on medical items should be reinvested in the health care supply chain
Seven ways to reinvest tariffs on medical items to create a strong and resilient health care supply chain.
How to get started with AI agents (and do it right)
When should enterprises build custom in-house AI agents, adopt third-party models, or use open source tools?
The Backbone of Virtual Healthcare: Ensuring Seamless Connectivity Anywhere
Virtual healthcare – including telemedicine and remote patient monitoring – has quickly become a staple in healthcare systems across the globe
Spotify’s share surge arrives at AI crossroads
Daniel Ek is cranking up the volume at Spotify Technology . Two years ago, the U.S.-listed music streamer faced heat from activist investor ValueAct Capital…
Israel Defies Expectations With Surge in Tech Funding Despite War
The 28% increase buoyed the country as it battled on several fronts but investment remains down from 2021
Ajit Lalvani: pioneering responses to major respiratory infections
Researcher Ajit Lalvani is a pioneer in the understanding of immune responses to respiratory infections and in translating that knowledge to improve care. He is…
Predatory journals: what can we do to protect their prey?
Authors, institutions, funders, and editors must be alert to the dangers A growing number of entities misrepresent themselves as scholarly journals for financial gain despite…
Revolutionizing Startups: Dassault Systèmes’ 3DEXPERIENCE Lab Empowering Entrepreneurs with AI and Sustainability Initiatives
Podcast Episode · What’s Up with Tech? · 01/09/2025 · 9m
Bayer pharma chief sees no big acquisitions in near future
Bayer will focus on paying down debt and not make any major acquisitions in the next two or three years, the head of the German…